首页> Nature cell biology> ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sarah Theresa,Boyle

第一单位： Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.

作者： Sarah Theresa,Boyle ^[1] ; Valentina,Poltavets ^[1] ; Jasreen,Kular ^[1] ; Natasha Theresa,Pyne ^[1] ; Jarrod John,Sandow ^[2] ; Alexander Charles,Lewis ^[3] ; Kendelle Joan,Murphy ^[4] ; Natasha,Kolesnikoff ^[1] ; Paul Andre Bartholomew,Moretti ^[1] ; Melinda Nay,Tea ^[1] ; Vinay,Tergaonkar ^[5] ; Paul,Timpson ^[4] ; Stuart Maxwell,Pitson ^[6] ; Andrew Ian,Webb ^[2] ; Robert John,Whitfield ^[7] ; Angel Francisco,Lopez ^[6] ; Marina,Kochetkova ^[8] ; Michael Susithiran,Samuel ^[9]

作者单位： Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia. ^[1] Division of Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.;Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia. ^[2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.;Translational Haematology Program, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia. ^[3] The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia. ^[4] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.;Institute of Molecular and Cell Biology, A*STAR and Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ^[5] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.;Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. ^[6] Breast, Endocrine and Surgical Oncology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. ^[7] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia. Marina.Kochetkova@unisa.edu.au. ^[8] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia. Michael.Samuel@unisa.edu.au.;Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. Michael.Samuel@unisa.edu.au. ^[9]